Olivopontocerebellar Atrophy Overview
Learn About Olivopontocerebellar Atrophy
- Olivopontocerebellar atrophy
- OPCA
University Of Cincinnati Physicians Company LLC
Alberto Espay is a Neurologist in Cincinnati, Ohio. Dr. Espay and is rated as a Distinguished provider by MediFind in the treatment of Olivopontocerebellar Atrophy. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Focal Dystonia, Conversion Disorder, and Deep Brain Stimulation. Dr. Espay is currently accepting new patients.
University Of Cincinnati Physicians Company LLC
Cara Jacob is a Neurologist in Cincinnati, Ohio. Dr. Jacob and is rated as an Advanced provider by MediFind in the treatment of Olivopontocerebellar Atrophy. Her top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Focal Dystonia, and Corticobasal Degeneration. Dr. Jacob is currently accepting new patients.
Trihealth H LLC
Paula Lafranconi is an Internal Medicine provider in Cincinnati, Ohio. Dr. Lafranconi and is rated as an Experienced provider by MediFind in the treatment of Olivopontocerebellar Atrophy. Her top areas of expertise are Familial Combined Hyperlipidemia, Xanthoma, Cirrhosis, and Type 2 Diabetes (T2D). Dr. Lafranconi is currently accepting new patients.
Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to c...
Summary: Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center